Literature DB >> 27833468

Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.

J Curtis Nickel1, Michael A Gorin2, Partin Alan W2, Stacy Loeb3, Shapiro Ellen3, Michael B Chancellor4, Dean G Assimos5, Michael K Brawer6, Benjamin M Brucker3.   

Abstract

Keywords:  Active surveillance; Disorders of sexual development; Four kallikrein assay; Genomic prostate score; Hemorrhagic cystitis; Inflammation; Microbiome; Nephrolithiasis; OnabotulinumtoxinA; Overactive bladder; Prostate cancer

Year:  2016        PMID： 27833468      PMCID： PMC5102934          DOI： 10.3909/riu0717

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  16 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  Preliminary Evidence Suggests Periureteral Botulinum Toxin Type A Injection Improves Ureteral Stone Passage in the Porcine Model.

Authors:  Necole M Streeper; Stephen Y Nakada; Margaret L Wertheim; Sara L Best
Journal:  J Endourol       Date:  2016-01-29       Impact factor: 2.942

Review 3.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

4.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

Review 6.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

7.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Authors:  Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

8.  The prognostic significance of perineural invasion and race in men considering active surveillance.

Authors:  Joshua A Cohn; Pankaj P Dangle; Chihsiung E Wang; Charles B Brendler; Kristian R Novakovic; Michael S McGuire; Brian T Helfand
Journal:  BJU Int       Date:  2014-01-22       Impact factor: 5.588

9.  How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.

Authors:  Stacy Loeb; Dawn Walter; Caitlin Curnyn; Heather T Gold; Herbert Lepor; Danil V Makarov
Journal:  J Urol       Date:  2016-03-02       Impact factor: 7.450

10.  The gonads of 111 South African patients with ovotesticular disorder of sex differentiation.

Authors:  Rinus Wiersma; P K Ramdial
Journal:  J Pediatr Surg       Date:  2009-03       Impact factor: 2.545
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.